MovDisordV3, Main, Exploration, bibRecord, 002342

Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

Identifieur interne : 002342 ( Main/Exploration ); précédent : 002341; suivant : 002343

Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

Auteurs : Robert A. Hauser [États-Unis] ; Michel Panisset [Canada] ; Giovanni Abbruzzese [Italie] ; Linda Mancione [États-Unis] ; Nalina Dronamraju [États-Unis] ; Algirdas Kakarieka [Suisse]

Source :

Movement Disorders [ 0885-3185 ] ; 2009-03-15.

RBID : ISTEX:040A5F110A6A28ADFF13CCEDF4A94E8B38A8CF05

Descripteurs français

Pascal (Inist)
- Carbidopa, Entacapone, Etude comparative, Lévodopa, Maladie de Parkinson, Pathologie du système nerveux, Traitement.

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Carbidopa, Carbidopa (therapeutic use), Catechols (therapeutic use), Comparative study, Double-Blind Method, Drug Therapy, Combination, Entacapone, Female, Humans, Levodopa, Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Nitriles (therapeutic use), Outcome Assessment (Health Care) (methods), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Severity of Illness Index, Stalevo, Treatment, UPDRS, entacapone, levodopa, treatment.
MESH :
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Catechols, Levodopa, Nitriles.
- drug therapy : Parkinson Disease.
- methods : Outcome Assessment (Health Care).
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Severity of Illness Index.

Abstract

We performed a 39‐week, randomized, double‐blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty‐three patients with early PD warranting levodopa were randomly assigned to treatment with LCE 100/25/200 or LC 100/25 three‐times daily. The adjusted mean difference in total Unified Parkinson's disease Rating Scale (UPDRS) Parts II and III between groups using the analysis of covariance model (prespecified primary outcome measure) was 1.7 (standard error = 0.84) points favoring LCE (P = 0.045). Significantly greater improvement with LCE compared with LC was also observed in UPDRS Part II activities of daily living (ADL) scores (P = 0.025), Schwab and England ADL scores (blinded rater, P = 0.003; subject, P = 0.006) and subject‐reported Clinical Global Impression (CGI) scores (P = 0.047). There was no significant difference in UPDRS Part III or investigator‐rated CGI scores. Wearing‐off was observed in 29 (13.9%) subjects in the LCE group and 43 (20.0%) in the LC group (P = 0.099). Dyskinesia was observed in 11 (5.3%) subjects in the LCE group and 16 (7.4%) in the LC group (P = 0.367). Nausea and diarrhea were reported more frequently in the LCE group. LCE provided greater symptomatic benefit than LC and did not increase motor complications. © 2008 Movement Disorder Society

Url:

https://api.istex.fr/document/040A5F110A6A28ADFF13CCEDF4A94E8B38A8CF05/fulltext/pdf

DOI: 10.1002/mds.22343

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name>
</author>
<author><name sortKey="Abbruzzese, Giovanni" sort="Abbruzzese, Giovanni" uniqKey="Abbruzzese G" first="Giovanni" last="Abbruzzese">Giovanni Abbruzzese</name>
</author>
<author><name sortKey="Mancione, Linda" sort="Mancione, Linda" uniqKey="Mancione L" first="Linda" last="Mancione">Linda Mancione</name>
</author>
<author><name sortKey="Dronamraju, Nalina" sort="Dronamraju, Nalina" uniqKey="Dronamraju N" first="Nalina" last="Dronamraju">Nalina Dronamraju</name>
</author>
<author><name sortKey="Kakarieka, Algirdas" sort="Kakarieka, Algirdas" uniqKey="Kakarieka A" first="Algirdas" last="Kakarieka">Algirdas Kakarieka</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:040A5F110A6A28ADFF13CCEDF4A94E8B38A8CF05</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22343</idno>
<idno type="url">https://api.istex.fr/document/040A5F110A6A28ADFF13CCEDF4A94E8B38A8CF05/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000369</idno>
<idno type="wicri:Area/Istex/Curation">000369</idno>
<idno type="wicri:Area/Istex/Checkpoint">000F44</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hauser R:double:blind:trial</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19058133</idno>
<idno type="wicri:Area/PubMed/Corpus">001F15</idno>
<idno type="wicri:Area/PubMed/Curation">001F15</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001E45</idno>
<idno type="wicri:Area/Ncbi/Merge">002450</idno>
<idno type="wicri:Area/Ncbi/Curation">002450</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002450</idno>
<idno type="wicri:Area/Main/Merge">002C03</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0171610</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F31</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D88</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000F04</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hauser R:double:blind:trial</idno>
<idno type="wicri:Area/Main/Merge">003001</idno>
<idno type="wicri:Area/Main/Curation">002342</idno>
<idno type="wicri:Area/Main/Exploration">002342</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center of Excellence, University of South Florida, Tampa, FL</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>André‐Barbeau Movement Disorders Unit, Department of Medicine (Neurology), University of Montreal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Abbruzzese, Giovanni" sort="Abbruzzese, Giovanni" uniqKey="Abbruzzese G" first="Giovanni" last="Abbruzzese">Giovanni Abbruzzese</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurological Sciences, Movement Disorder Unit, University of Genoa, Genoa</wicri:regionArea>
<wicri:noRegion>Genoa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mancione, Linda" sort="Mancione, Linda" uniqKey="Mancione L" first="Linda" last="Mancione">Linda Mancione</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceuticals, East Hanover, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dronamraju, Nalina" sort="Dronamraju, Nalina" uniqKey="Dronamraju N" first="Nalina" last="Dronamraju">Nalina Dronamraju</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceuticals, East Hanover, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kakarieka, Algirdas" sort="Kakarieka, Algirdas" uniqKey="Kakarieka A" first="Algirdas" last="Kakarieka">Algirdas Kakarieka</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-03-15">2009-03-15</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="541">541</biblScope>
<biblScope unit="page" to="550">550</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">040A5F110A6A28ADFF13CCEDF4A94E8B38A8CF05</idno>
<idno type="DOI">10.1002/mds.22343</idno>
<idno type="ArticleID">MDS22343</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Carbidopa</term>
<term>Carbidopa (therapeutic use)</term>
<term>Catechols (therapeutic use)</term>
<term>Comparative study</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Entacapone</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Nitriles (therapeutic use)</term>
<term>Outcome Assessment (Health Care) (methods)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Severity of Illness Index</term>
<term>Stalevo</term>
<term>Treatment</term>
<term>UPDRS</term>
<term>entacapone</term>
<term>levodopa</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Catechols</term>
<term>Levodopa</term>
<term>Nitriles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Outcome Assessment (Health Care)</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Carbidopa</term>
<term>Entacapone</term>
<term>Etude comparative</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a 39‐week, randomized, double‐blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty‐three patients with early PD warranting levodopa were randomly assigned to treatment with LCE 100/25/200 or LC 100/25 three‐times daily. The adjusted mean difference in total Unified Parkinson's disease Rating Scale (UPDRS) Parts II and III between groups using the analysis of covariance model (prespecified primary outcome measure) was 1.7 (standard error = 0.84) points favoring LCE (P = 0.045). Significantly greater improvement with LCE compared with LC was also observed in UPDRS Part II activities of daily living (ADL) scores (P = 0.025), Schwab and England ADL scores (blinded rater, P = 0.003; subject, P = 0.006) and subject‐reported Clinical Global Impression (CGI) scores (P = 0.047). There was no significant difference in UPDRS Part III or investigator‐rated CGI scores. Wearing‐off was observed in 29 (13.9%) subjects in the LCE group and 43 (20.0%) in the LC group (P = 0.099). Dyskinesia was observed in 11 (5.3%) subjects in the LCE group and 16 (7.4%) in the LC group (P = 0.367). Nausea and diarrhea were reported more frequently in the LCE group. LCE provided greater symptomatic benefit than LC and did not increase motor complications. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Italie</li>
<li>Suisse</li>
<li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>New Jersey</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
<name sortKey="Dronamraju, Nalina" sort="Dronamraju, Nalina" uniqKey="Dronamraju N" first="Nalina" last="Dronamraju">Nalina Dronamraju</name>
<name sortKey="Mancione, Linda" sort="Mancione, Linda" uniqKey="Mancione L" first="Linda" last="Mancione">Linda Mancione</name>
</country>
<country name="Canada"><noRegion><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name>
</noRegion>
</country>
<country name="Italie"><noRegion><name sortKey="Abbruzzese, Giovanni" sort="Abbruzzese, Giovanni" uniqKey="Abbruzzese G" first="Giovanni" last="Abbruzzese">Giovanni Abbruzzese</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Kakarieka, Algirdas" sort="Kakarieka, Algirdas" uniqKey="Kakarieka A" first="Algirdas" last="Kakarieka">Algirdas Kakarieka</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002342 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002342 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:040A5F110A6A28ADFF13CCEDF4A94E8B38A8CF05
   |texte=   Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.